Bladder EpiCheck urine test

DEVICE2 trials

Sponsors

Nucleix Ltd., White River Junction Veterans Affairs Medical Center

Conditions

Bladder CancerNon-muscle-invasive Bladder Cancer

Phase 2

Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance

RecruitingNCT05796375

White River Junction Veterans Affairs Medical CenterNon-muscle-invasive Bladder Cancer

Start: 2023-11-17End: 2028-12-30Target: 240Updated: 2026-09-16

Unknown Phase

The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma

CompletedNCT02700464

Nucleix Ltd.Bladder Cancer

Start: 2016-09-30End: 2020-07-31Updated: 2021-05-04

Related Papers

PD48-07 PIVOTAL STUDY EVALUATING PERFORMANCE OF BLADDER EPICHECK, AN FDA CLEARED TEST, IN NON-MUSCLE INVASIVE BLADDER CANCER

The Journal of Urology2024-04-15

Clinical Trial Protocol for “Replace Cysto”: Replacing Invasive Cystoscopy with Urine Testing for Non–muscle-invasive Bladder Cancer Surveillance—A Multicenter, Randomized, Phase 2 Healthcare Delivery Trial Comparing Quality of Life During Cancer Surveillance with Xpert Bladder Cancer Monitor or Bladder EpiCheck Urine Testing Versus Frequent Cystoscopy

European Urology Open Science2024-03-2212 citations